2024
Rethinking the Abnormal Uterine Bleeding Consult: Creating a Patient-Centered, See-and-Treat Model of Care
Robinson E, Desai V, Chudnoff S. Rethinking the Abnormal Uterine Bleeding Consult: Creating a Patient-Centered, See-and-Treat Model of Care. O&G Open 2024, 1: 008. DOI: 10.1097/og9.0000000000000008.Peer-Reviewed Original ResearchAbnormal uterine bleedingPatient-centeredEvaluation of abnormal uterine bleedingClinical care modelsHealth care efficiencyAssessed patients' historyPhysician engagementUterine assessmentCare modelUterine bleedingCare settingsPatient experienceGynecologic conditionsCare efficiencyOutpatient procedureIn-officePatient historyOutpatient settingCoronavirus disease 2019Operating roomClinical practiceLearning curveCareCOVID-19COVID-19 pandemicAbnormal uterine bleeding diagnoses and care following COVID-19 vaccination
Brooks N, Irving S, Kauffman T, Vesco K, Slaughter M, Smith N, Tepper N, Olson C, Weintraub E, Naleway A, Group V, DeNoble A, DeSilva M, Ellington S, Henninger M, Jazwa A, Kharbanda E, Lipkind H, Malden D, McNeil M, Tartof S, Zerbo O. Abnormal uterine bleeding diagnoses and care following COVID-19 vaccination. American Journal Of Obstetrics And Gynecology 2024, 230: 540.e1-540.e13. PMID: 38219855, DOI: 10.1016/j.ajog.2024.01.006.Peer-Reviewed Original ResearchAUB diagnosisAbnormal uterine bleedingAbnormal uterine bleeding casesUterine bleedingBleeding diagnosisAbnormal bleedingCOVID-19 vaccineChart reviewVaccinated patientsBleeding casesHealth system membersVaccination statusFemale patients of reproductive ageComparison of clinical characteristicsChart review of patientsPatients of reproductive ageProportion of Asian patientsDays of COVID-19 vaccinationReview of patientsVolume of bleedingProportion of patientsDemographic characteristics of patientsPost-COVID-19 vaccinationCharacteristics of patientsRace of patients
2023
Ovarian Leydig Cell Tumor Associated with Recurrent Torsion and Virilization in an Adolescent Patient
Roth L, Smith A, Buza N, Coons B, Stitelman D, Vash-Margita A. Ovarian Leydig Cell Tumor Associated with Recurrent Torsion and Virilization in an Adolescent Patient. Journal Of Pediatric And Adolescent Gynecology 2023, 37: 217-219. PMID: 38110028, DOI: 10.1016/j.jpag.2023.11.014.Peer-Reviewed Original ResearchPolycystic ovarian syndromeOvarian tumorsCell tumorsRecurrent ovarian torsionAbnormal uterine bleedingPost-menopausal womenLeydig cell tumorUterine bleedingOvarian syndromeOvarian torsionYounger patientsOvarian functionOvarian hilumAdolescent patientsNodular proliferationSecrete androgensTumor AssociatedRecurrent torsionPrimary amenorrheaCurrent recommendationsReinke crystalsTumorsLeydig cellsIncidence increasesVirilizationImpact of iron supplementation on patient outcomes for women with abnormal uterine bleeding: a protocol for a systematic review and meta-analysis
Nazaryan H, Watson M, Ellingham D, Thakar S, Wang A, Pai M, Liu Y, Rochwerg B, Gabarin N, Arnold D, Sirotich E, Zeller M. Impact of iron supplementation on patient outcomes for women with abnormal uterine bleeding: a protocol for a systematic review and meta-analysis. Systematic Reviews 2023, 12: 121. PMID: 37443063, PMCID: PMC10347734, DOI: 10.1186/s13643-023-02222-4.Peer-Reviewed Original ResearchConceptsIron deficiency anemiaQuality of lifeHeavy menstrual bleedingStandard of carePatient outcomesIron interventionsSystematic reviewUterine bleedingCombination therapyIron supplementationIron indicesRed blood cell transfusionIron deficiencyRed blood cell utilizationAbnormal uterine bleedingIntraoperative blood lossBlood cell transfusionEvidence-based clinical practiceMeta-analyzed outcomesSystematic literature searchCost of treatmentWeb of ScienceCell transfusionHospital stayAdverse eventsImproving the Health and Readiness of Military Women
Witkop C, Kostas-Polston E, Degutis L. Improving the Health and Readiness of Military Women. Military Medicine 2023, 188: 8-14. PMID: 36882034, DOI: 10.1093/milmed/usac354.Peer-Reviewed Original ResearchConceptsMilitary Health SystemPreventive health servicesUnintended pregnancyContraceptive methodsGeneral populationMilitary womenOptimal healthWomen's preventive health servicesAbnormal uterine bleedingReproductive health issuesMeasures of healthService delivery targetsGynecologic healthUterine bleedingContraceptive utilizationInfant outcomesGynecologic conditionsMenstrual cycleContraceptive optionsContraceptive useMedical conditionsMenstrual suppressionPregnancyHealth servicesContraceptive accessRacial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries
Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. Journal Of The National Cancer Institute 2023, 115: 636-643. PMID: 36788453, PMCID: PMC10248843, DOI: 10.1093/jnci/djad027.Peer-Reviewed Original ResearchConceptsAbnormal uterine bleedingWhite patientsUterine cancerFirst diagnostic procedureDiagnostic evaluationBlack patientsDiagnostic proceduresBlack-White disparitiesManagement visitsMarketScan Multi-State Medicaid DatabaseMulti-State Medicaid DatabaseUterine bleedingPatient characteristicsMedicaid databaseEarly diagnosisMedicaid beneficiariesMultivariable regressionPatientsCancerRacial disparitiesDiagnosisVisitsMore evaluationDisparitiesBleeding
2022
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
Donnez J, Taylor H, Stewart E, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland J, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey 2022, 77: 741-742. DOI: 10.1097/ogx.0000000000001113.Peer-Reviewed Original ResearchPost-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]
Taylor H, Donnez J, Bestel E, Humberstone A, Garner E. Post-treatment Efficacy and Safety Follow-up in Women with Uterine Fibroids Treated for 52 Weeks With Linzagolix [A108]. Obstetrics And Gynecology 2022, 139: 31s-32s. DOI: 10.1097/01.aog.0000826752.16466.97.Peer-Reviewed Original ResearchBone mineral densityUterine fibroidsWeek 64Placebo-controlled phase 3 trialLumbar spine bone mineral densityTreatment of UFsSpine bone mineral densityHeavy menstrual bleedingPhase 3 trialWeeks of dosingHealth-related qualityCompletion of treatmentTreatment of womenEfficacy endpointPost-treatment efficacyTreatment discontinuationUterine bleedingWeek 52Key efficacyWeek 76Menstrual bleedingFibroid volumeMedian timeFollow-upMineral density
2021
Amenorrhea and Abnormal Uterine Bleeding
Collins S, Martin J, Pal L. Amenorrhea and Abnormal Uterine Bleeding. 2021, 525-541. DOI: 10.1007/978-3-030-75385-6_49.Peer-Reviewed Original ResearchMenstrual cycleWorsening of anemiaAbnormal uterine bleedingImpaired nutritional statusManagement of patientsGeneral health issuesUterine bleedingMenstrual flowCommon causeLoss of fertilityNutritional statusInfectious diseasesAmenorrheaSuch disordersHealth issuesAbnormal durationSocial isolationBleedingPatientsAnemiaDysfunctionHypothalamusUterusWorseningAbnormalities
2020
Menstruation: science and society
Critchley HOD, Babayev E, Bulun SE, Clark S, Garcia-Grau I, Gregersen PK, Kilcoyne A, Kim JJ, Lavender M, Marsh EE, Matteson KA, Maybin JA, Metz CN, Moreno I, Silk K, Sommer M, Simon C, Tariyal R, Taylor HS, Wagner GP, Griffith LG. Menstruation: science and society. American Journal Of Obstetrics And Gynecology 2020, 223: 624-664. PMID: 32707266, PMCID: PMC7661839, DOI: 10.1016/j.ajog.2020.06.004.Peer-Reviewed Original ResearchMeSH KeywordsAdenomyosisAttitudeBiological EvolutionBiomedical ResearchCongresses as TopicDeveloping CountriesEducationEndometriosisEndometriumFemaleGlobal HealthHealth LiteracyHumansLeiomyomaMenstrual Hygiene ProductsMenstruationMenstruation DisturbancesMesenchymal Stem CellsMicrobiotaMicrofluidic Analytical TechniquesNational Institute of Child Health and Human Development (U.S.)RegenerationStem CellsTerminology as TopicTissue EngineeringUnited StatesUterine HemorrhageUterine NeoplasmsUterusWomen's HealthConceptsAbnormal uterine bleedingMenstruation-related disordersUterine bleedingEunice Kennedy Shriver National InstituteHealth concernScarless healing processWomen's health concernsMenstrual healthGynecologic healthUterine preservationMiddle-income countriesProgesterone withdrawalVascular functionClinical challengeHigh-income countriesEndometrial biologyChild healthHealth literacyMost womenHealthy individualsMenstrual physiologyOverall healthReproductive healthDisease BranchMenstruationDo High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net Hospital.
Kuhn T, Finneran C, Kohut A, Wang E, Birdsong G, Krishnamurti U, Mosunjac M, Tadros T, Oprea G, Avadhani V, Boguslawski S, Karlow S, Schnatz P, Khanna N, Flowers L. Do High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net Hospital. Journal Of Lower Genital Tract Disease 2020, 24: 353-357. PMID: 32569024, DOI: 10.1097/lgt.0000000000000556.Peer-Reviewed Original ResearchConceptsAGC Pap testsAbnormal uterine bleedingPap testUterine bleedingHPV positivityHuman papillomavirusLarge safety net hospitalBody mass indexHigh-risk lesionsLow-risk lesionsSafety-net hospitalLow socioeconomic statusBaseline characteristicsEndometrial biopsyMass indexSingle institutionMedical recordsNet hospitalHigh incidencePatientsLesionsSignificant associationHR lesionsBleedingLogistic regressionIncidental sonographic detection of bladder cancer in a woman with large uterine fibroids: significance and lessons learned
Soliman MM, Cornman-Homonoff J, Schiffman MH. Incidental sonographic detection of bladder cancer in a woman with large uterine fibroids: significance and lessons learned. Clinical Imaging 2020, 61: 1-3. PMID: 31945687, DOI: 10.1016/j.clinimag.2020.01.001.Peer-Reviewed Case Reports and Technical NotesConceptsLarge uterine fibroidsBladder cancerUterine fibroidsCommon solid pelvic tumorsEarly-stage bladder cancerSolid pelvic tumorsSpace-occupying natureAbnormal uterine bleedingPre-menopausal womenUterine fibroid embolizationUterine bleedingPelvic diseasePelvic pathologyPelvic tumorsFibroid embolizationSonographic detectionUterine leiomyomaImmediate followFibroidsMass effectWomenSymptomsCancerBleedingEmbolization
2018
Endometrial Carcinoma in a 26‐Year‐Old Patient with Bardet‐Biedl Syndrome
Grechukhina O, Gressel GM, Munday W, Wong S, Santin A, Vash-Margita A. Endometrial Carcinoma in a 26‐Year‐Old Patient with Bardet‐Biedl Syndrome. Case Reports In Obstetrics And Gynecology 2018, 2018: 1952351. PMID: 29854508, PMCID: PMC5960523, DOI: 10.1155/2018/1952351.Peer-Reviewed Original ResearchAbnormal uterine bleedingBardet-Biedl syndromeEndometrial cancerUterine bleedingRisk factorsDefinitive surgical treatmentIndependent risk factorEndometrioid endometrial adenocarcinomaRare genetic conditionOvulatory dysfunctionBilateral salpingectomyCentral obesityOlder patientsTruncal obesityYounger patientsEndometrioid adenocarcinomaSurgical treatmentEndometrial adenocarcinomaEndometrial carcinomaClinical signsCognitive impairmentPatientsCancerGenetic conditionsBleeding
2017
Treatment Modalities for Fibroids, Indications, Risks, and Benefits
Garg D, Segars J. Treatment Modalities for Fibroids, Indications, Risks, and Benefits. 2017, 87-106. DOI: 10.1007/978-3-319-58780-6_3.Peer-Reviewed Original ResearchTreatment modalitiesUterine fibroidsGonadotropin-releasing hormone agonistInvasive surgeryInterventional radiological approachAbnormal uterine bleedingTreatment of fibroidsManagement of fibroidsNew treatment optionsSize of fibroidsCommon benign neoplasmInterventional radiological proceduresFibroid managementAbdominal painHormonal therapyUrinary frequencyUterine bleedingProcedural indicationsPressure symptomsAbdominal girthHormone agonistMedical managementPatient's symptomsSurgical managementClinical manifestationsDysfunctional Uterine Bleeding Following Treatment with Bisphenol-A Glycidyl Methacrylate (BisGMA) Dental Resins
Aldad T, Lavian S, Rahmani N, Taylor H. Dysfunctional Uterine Bleeding Following Treatment with Bisphenol-A Glycidyl Methacrylate (BisGMA) Dental Resins. Journal Of Trauma & Treatment 2017, 06 DOI: 10.4172/2167-1222.1000365.Peer-Reviewed Original Research
2015
Progestins Upregulate FKBP51 Expression in Human Endometrial Stromal Cells to Induce Functional Progesterone and Glucocorticoid Withdrawal: Implications for Contraceptive- Associated Abnormal Uterine Bleeding
Kayisli O, Kayisli UA, Basar M, Semerci N, Schatz F, Lockwood CJ. Progestins Upregulate FKBP51 Expression in Human Endometrial Stromal Cells to Induce Functional Progesterone and Glucocorticoid Withdrawal: Implications for Contraceptive- Associated Abnormal Uterine Bleeding. PLOS ONE 2015, 10: e0137855. PMID: 26436918, PMCID: PMC4593551, DOI: 10.1371/journal.pone.0137855.Peer-Reviewed Original ResearchConceptsHuman endometrial stromal cellsAbnormal uterine bleedingEndometrial stromal cellsMedroxyprogesterone acetateGuinea pigsUterine bleedingCultured human endometrial stromal cellsStromal cellsGlandular cellsProgestin only contraceptivesEndometrial blood flowOvariectomized guinea pigsMajor side effectsEffective family planning methodsGlucocorticoid receptor activationGR transcriptional activityFragile blood vesselsFamily planning methodsIngenuity Pathway AnalysisFKBP51 expressionFunctional withdrawalMicroarray resultsOnly contraceptivesGlucocorticoid withdrawalEndometrial inflammation
2014
Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells
Shapiro JP, Basar M, Kayisli UA, Guzeloglu-Kayisli O, Huang S, Suarez AA, Ozer HG, Schatz F, Lockwood CJ. Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells. Contraception 2014, 91: 253-260. PMID: 25529278, PMCID: PMC4395468, DOI: 10.1016/j.contraception.2014.11.005.Peer-Reviewed Original ResearchConceptsHuman endometrial stromal cellsAbnormal uterine bleedingEndometrial stromal cellsUterine bleedingStanniocalcin-1Cultured human endometrial stromal cellsStromal cellsMicroarray analysisEndometrial biopsyTubal metaplasiaMRNA microarray analysisSide effectsLAPCComplex biological responseEtonogestrelHypoxia treatmentProgestinsHypoxiaPrimary culturesPotential mediatorsPotential targetProtein mediatorsBleedingExpression levelsMedium supernatantUterine Fibroids: Clinical Manifestations and Contemporary Management
Doherty L, Mutlu L, Sinclair D, Taylor H. Uterine Fibroids: Clinical Manifestations and Contemporary Management. Reproductive Sciences 2014, 21: 1067-1092. PMID: 24819877, DOI: 10.1177/1933719114533728.Peer-Reviewed Original ResearchConceptsMedical therapyUterine fibroidsGrowth factorAbnormal uterine bleedingHeavy menstrual bleedingInterventional radiological proceduresEndometrial effectsUterine bleedingMenstrual bleedingMedical managementSurgical managementCommon lesionsCurrent armamentariumFibroid treatmentClinical trialsEffective treatmentFibroidsRadiological proceduresDrug AdministrationFibroid cellsNovel therapeuticsAbnormal regulationTherapyFibroid biologyMolecular changesDifferential effects of menopausal therapies on the endometrium
Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause The Journal Of The North American Menopause Society 2014, 21: 899-908. PMID: 24518153, DOI: 10.1097/gme.0000000000000186.Peer-Reviewed Original ResearchConceptsTissue selective estrogen complexSelective estrogen receptor modulatorsEstrogen-progestin therapyEndometrial profileEndometrial safetyEndometrial effectsEstrogen therapyMenopausal symptomsEstrogen receptor degradationNew hormone therapiesIndividual selective estrogen receptor modulatorsIrregular uterine bleedingIncidence of hyperplasiaEstrogen receptor modulatorsMenopausal therapyTolerability profileUterine bleedingEndometrial proliferationHormone therapyPostmenopausal womenEndometrial cancerClinical findingsSafety profileAvailable treatmentsReceptor modulatorsLong-Acting Progestin-Only Contraceptives Enhance Human Endometrial Stromal Cell Expressed Neuronal Pentraxin-1 and Reactive Oxygen Species to Promote Endothelial Cell Apoptosis
Guzeloglu-Kayisli O, Basar M, Shapiro J, Semerci N, Huang J, Schatz F, Lockwood C, Kayisli U. Long-Acting Progestin-Only Contraceptives Enhance Human Endometrial Stromal Cell Expressed Neuronal Pentraxin-1 and Reactive Oxygen Species to Promote Endothelial Cell Apoptosis. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: e1957-e1966. PMID: 25029423, PMCID: PMC4184079, DOI: 10.1210/jc.2014-1770.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisC-Reactive ProteinCaspase 3Cell ProliferationCells, CulturedContraceptive Agents, FemaleCulture Media, ConditionedCytochromes cEndometriumEndothelial CellsEstradiolFemaleHumansMedroxyprogesterone AcetateMicrovesselsNerve Tissue ProteinsParacrine CommunicationProgestinsReactive Oxygen SpeciesStromal CellsConceptsHuman endometrial endothelial cellsNeuronal pentraxin 1Abnormal uterine bleedingUterine bleedingMedroxyprogesterone acetateReactive oxygen species generationCultured human endometrial endothelial cellsOxygen species generationHuman endometrial stromal cellsUterine blood flowEndometrium of womenEndometrial endothelial cellsEndometrial stromal cellsProgesterone receptor proteinCaspase-3Elevated reactive oxygen species (ROS) generationHESC-CMsNovel paracrine mechanismEndothelial cell apoptosisSpecies generationFragile microvesselsCytosolic cytochrome c levelsParacrine mechanismsBlood flowLAPC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply